Comparative Pharmacology
Head-to-head clinical analysis: TRINTELLIX versus ZYBAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRINTELLIX versus ZYBAN.
TRINTELLIX vs ZYBAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trintellix (vortioxetine) is a serotonin modulator and reuptake inhibitor. Its exact mechanism is not fully understood, but it is thought to work by inhibiting the reuptake of serotonin (5-HT) and by modulating several serotonin receptors, including 5-HT1A agonism, 5-HT1B partial agonism, 5-HT3 and 5-HT7 antagonism.
Bupropion is a selective dopamine and norepinephrine reuptake inhibitor with weak inhibition of serotonin reuptake. Its mechanism in smoking cessation and depression is not fully understood.
10 mg orally once daily initially, then increase to 20 mg orally once daily based on tolerability; maximum 20 mg/day.
150 mg orally once daily for 3 days, then increase to 150 mg twice daily for a total treatment duration of 7-12 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 66 hours (range 58-78 hours) for vortioxetine. This supports once-daily dosing; steady-state is reached within 2-3 weeks.
The terminal elimination half-life of bupropion is approximately 21 hours (range 18-24 h), while its active metabolites have longer half-lives: hydroxybupropion ~20 h, threohydrobupropion ~37 h, erythrohydrobupropion ~33 h. Steady state is achieved within 8 days.
Primarily hepatic metabolism via CYP3A4 and CYP2C19, with approximately 26% of the dose recovered in urine (mostly as metabolites) and 60% in feces (mostly as metabolites). Less than 1% excreted as unchanged drug in urine.
Renal excretion accounts for approximately 87% of an oral dose, with 42% as unchanged bupropion and its active metabolites (hydroxybupropion, threohydrobupropion, erythrohydrobupropion). Fecal excretion is minimal at <10%.
Category C
Category C
Antidepressant
Antidepressant, Smoking Cessation Aid